Panbela Announces Acceptance of Abstract for Poster Presentation at American Society of Clinical Oncology Gastrointestinal Cancers Symposium
MINNEAPOLIS, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today announced that an abstract for SBP-101, a proprietary polyamine analogue, has been accepted for poster presentation at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, which will be held January 20-22, 2022.
Details of the presentation are as follows:
Additional meeting information can be found on the ASCO website https://meetings.asco.org/gi/. The full abstract will be made available online via https://meetinglibrary.asco.org at 5:00 PM (EST) on January 18, 2022.
Cautionary Statement Regarding Forward-Looking Statements
Top Trends in Enterprise Digital Infrastructure and How to Leverage Them
Getting to the Relevant (meta) Data
How Verification is Helping Maintain the Integrity of Voice Calls